Alexion Pharmaceuticals Inc (NASDAQ:ALXN) Institutional Investor Sentiment Trend

Marco Green
April 27, 2018

Diamond Hill Capital Management Inc sold 18,260 shares as the company's stock declined 13.23% with the market. The institutional investor held 17,283 shares of the health care company at the end of 2017Q4, valued at $2.07M, up from 10,614 at the end of the previous reported quarter.

Sterling Capital Management Llc increased Alexion Pharmaceuticals Inc Co (ALXN) stake by 491.59% reported in 2017Q4 SEC filing. The stock increased 0.43% or $0.25 during the last trading session, reaching $58.7. About 3.40M shares traded or 54.51% up from the average.

Alexion Pharmaceuticals (NASDAQ:ALXN) posted its quarterly earnings data on Wednesday. It has underperformed by 20.39% the S&P500.

Alexion Pharmaceuticals Inc (NASDAQ:ALXN) institutional sentiment decreased to 1.03 in Q4 2017. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 103,254 shares of the biopharmaceutical company's stock worth $12,348,000 after acquiring an additional 8,997 shares in the last quarter. About 290,517 shares traded or 54.22% up from the average. (NYSE:AJRD) has risen 27.60% since April 27, 2017 and is uptrending. It has outperformed by 30.28% the S&P500.

Kazazian Asset Management Llc, which manages about $97.87M US Long portfolio, decreased its stake in Biogen Inc (NASDAQ:BIIB) by 1,272 shares to 9,229 shares, valued at $2.94 million in 2017Q4, according to the filing.

Investors sentiment increased to 0.81 in Q4 2017. Its down 0.14, from 1.17 in 2017Q3. The ratio has dropped, as 23 institutional investors increased or started new holdings, while 16 sold and reduced stock positions in LCNB Corp. The active investment managers in our database now possess: 4.92 million shares, down from 5.36 million shares in 2017Q3. Macquarie Grp Incorporated reported 201,245 shares. $83,305 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 53,327 shares. Stephens Investment Management Gp reported 21,296 shares. State Of New Jersey Common Pension Fund D has invested 0.12% of its portfolio in Alexion Pharmaceuticals, Inc. Rock Springs Cap Lp holds 2.6% or 480,000 shares. 26,298 were accumulated by Btc Mngmt Incorporated. Tudor Invest Et Al has 2,264 shares for 0.01% of their portfolio. (NASDAQ:ALXN) for 166,042 shares. Honeywell International invested 0.91% in Alexion Pharmaceuticals, Inc. Pub Employees Retirement Sys Of Ohio holds 0.22% or 337,108 shares. Hightower Advsr Ltd Company holds 4,464 shares or 0% of its portfolio. Citigroup holds 0.01% or 148,438 shares. (NYSE:BCE), 5 have Buy rating, 1 Sell and 3 Hold. Therefore 93% are positive. Wedbush initiated Fiserv, Inc. (NYSE:BCE) earned "Overweight" rating by Barclays Capital on Friday, February 9. The stock of Banco Macro S.A. (NYSE:BMA) has "Buy" rating given on Monday, September 26 by Goldman Sachs. (NASDAQ:ALXN), 25 have Buy rating, 0 Sell and 4 Hold. Sterne Agee CRT initiated Fiserv, Inc. Raymond James downgraded the stock to "Outperform" rating in Thursday, January 4 report. Robert W. Baird maintained Fiserv, Inc. The firm has "Neutral" rating given on Wednesday, June 1 by UBS. Roth Capital has "Buy" rating and $4100 target. The company was maintained on Thursday, February 8 by BMO Capital Markets. As per Tuesday, August 15, the company rating was maintained by Oppenheimer. (NASDAQ:FISV) earned "Sector Weight" rating by Pacific Crest on Friday, November 18.

Since January 1, 0001, it had 2 buys, and 0 selling transactions for $28,260 activity. $76,805 worth of stock was sold by Wagner Heidi L on Monday, February 5. BidaskClub upgraded Alexion Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research note on Wednesday, December 27th. Comml Bank Of America Corporation De reported 1.62 million shares. The insider VIELEHR BYRON C sold $1.31 million.

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. Therefore 86% are positive. Natus Medical had 11 analyst reports since July 23, 2015 according to SRatingsIntel. The firm has "Neutral" rating by Wedbush given on Friday, September 23.

CEO, Hantson Ludwig, sold 13,245 common shares of Alexion Pharmaceuticals, Inc. The company was upgraded on Friday, October 28 by FBR Capital. Suntrust Robinson initiated the shares of AJRD in report on Thursday, January 19 with "Buy" rating.

Currently, the analyst consensus on Alexion Pharmaceuticals is Strong Buy and the average price target is $159.25, representing a 31.2% upside. Alexion Pharmaceuticals had a net margin of 12.48% and a return on equity of 12.94%. (ALXN) in trading session dated February 28, 2018. Nomura has "Buy" rating and $14800 target. (NASDAQ:ALXN). Hbk L P owns 0% invested in Alexion Pharmaceuticals, Inc. The stock has "Buy" rating by Piper Jaffray on Thursday, February 8. The firm has "Buy" rating given on Friday, October 27 by Stifel Nicolaus. Tobam owns 1.73% invested in Alexion Pharmaceuticals, Inc.

Since January 2, 2018, it had 0 buys, and 12 insider sales for $4.62 million activity. O'Neill Julie also sold $194,723 worth of Alexion Pharmaceuticals, Inc. Also, EVP John B. Moriarty sold 3,363 shares of the firm's stock in a transaction that occurred on Thursday, February 8th. Goff Brian sold 1,651 shares worth $192,028. (NASDAQ:ALXN) shares. Franchini Indrani Lall sold $169,696 worth of Alexion Pharmaceuticals, Inc.

A number of equities research analysts recently issued reports on ALXN shares.

Bank Of The West, which manages about $798.51M US Long portfolio, upped its stake in Select Sector Spdr Tr by 11,828 shares to 19,699 shares, valued at $649,000 in 2017Q4, according to the filing.

Other reports by Click Lancashire

Discuss This Article